458 related articles for article (PubMed ID: 24099468)
1. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
Musumba CO
Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
[TBL] [Abstract][Full Text] [Related]
2. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine.
Seksik P; Mary JY; Beaugerie L; Lémann M; Colombel JF; Vernier-Massouille G; Cosnes J
Inflamm Bowel Dis; 2011 Feb; 17(2):565-72. PubMed ID: 20848502
[TBL] [Abstract][Full Text] [Related]
3. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
Seinen ML; van Asseldonk DP; de Boer NK; Bouma G; van Nieuwkerk CM; Mulder CJ; Bloemena E; van Bodegraven AA
Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
[TBL] [Abstract][Full Text] [Related]
4. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
Taylor KM; Ward MG; Blaker PA; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
Gilissen LPL; Tajzai R; Romberg M; Pierik M; Stronkhorst A; Steenhuisen K; Van Bodegraven A; Daniels A; Wong D
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e102-e107. PubMed ID: 33136726
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
Bayoumy AB; van Liere ELSA; Simsek M; Warner B; Loganayagam A; Sanderson JD; Anderson S; Nolan J; de Boer NK; Mulder CJJ; Ansari A
BMC Gastroenterol; 2020 Sep; 20(1):296. PubMed ID: 32917155
[TBL] [Abstract][Full Text] [Related]
7. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
Simsek M; Meijer B; Ramsoekh D; Bouma G; van der Wouden EJ; den Hartog B; de Vries AC; Hoentjen F; Dijkstra G; de Boer SY; Jansen JM; van der Meulen AE; Beukers R; Brink MA; Steinhauser T; Oldenburg B; Gilissen LP; Naber TH; Verhagen MA; de Boer NKH; Mulder CJJ;
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):568-570. PubMed ID: 29775790
[TBL] [Abstract][Full Text] [Related]
8. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
De Boer NK; Tuynman H; Bloemena E; Westerga J; Van Der Peet DL; Mulder CJ; Cuesta MA; Meuwissen SG; Van Nieuwkerk CM; Van Bodegraven AA
Scand J Gastroenterol; 2008; 43(5):604-8. PubMed ID: 18415755
[TBL] [Abstract][Full Text] [Related]
9. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
Cohen-Ezra O; Avni Y; Morgenstern S; Ben-Ari Z
Harefuah; 2012 Dec; 151(12):675-8, 721. PubMed ID: 23330258
[TBL] [Abstract][Full Text] [Related]
10. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.
Vernier-Massouille G; Cosnes J; Lemann M; Marteau P; Reinisch W; Laharie D; Cadiot G; Bouhnik Y; De Vos M; Boureille A; Duclos B; Seksik P; Mary JY; Colombel JF
Gut; 2007 Oct; 56(10):1404-9. PubMed ID: 17504943
[TBL] [Abstract][Full Text] [Related]
11. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.
Seiderer J; Zech CJ; Diebold J; Schoenberg SO; Brand S; Tillack C; Göke B; Ochsenkühn T
Eur J Gastroenterol Hepatol; 2006 May; 18(5):553-5. PubMed ID: 16607155
[TBL] [Abstract][Full Text] [Related]
12. Azathioprine induced nodular regenerative hyperplasia in IBD patients.
Daniel F; Cadranel JF; Seksik P; Cazier A; Duong Van Huyen JP; Ziol M; Coutarel P; Loison P; Jian R; Marteau P
Gastroenterol Clin Biol; 2005 May; 29(5):600-3. PubMed ID: 15980758
[TBL] [Abstract][Full Text] [Related]
13. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
van Asseldonk DP; Jharap B; Verheij J; den Hartog G; Westerveld DB; Becx MC; Russel MG; Engels LG; de Jong DJ; Witte BI; Mulder CJ; van Nieuwkerk CM; Bloemena E; de Boer NK; van Bodegraven AA
Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972
[TBL] [Abstract][Full Text] [Related]
14. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
[TBL] [Abstract][Full Text] [Related]
15. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
Dubinsky MC; Vasiliauskas EA; Singh H; Abreu MT; Papadakis KA; Tran T; Martin P; Vierling JM; Geller SA; Targan SR; Poordad FF
Gastroenterology; 2003 Aug; 125(2):298-303. PubMed ID: 12891528
[TBL] [Abstract][Full Text] [Related]
16. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
Calabrese E; Hanauer SB
J Crohns Colitis; 2011 Feb; 5(1):48-53. PubMed ID: 21272804
[TBL] [Abstract][Full Text] [Related]
17. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
Dubinsky MC
Clin Gastroenterol Hepatol; 2004 Sep; 2(9):731-43. PubMed ID: 15354273
[TBL] [Abstract][Full Text] [Related]
18. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Kennedy NA; Rhatigan E; Arnott ID; Noble CL; Shand AG; Satsangi J; Lees CW
Aliment Pharmacol Ther; 2013 Nov; 38(10):1255-66. PubMed ID: 24117596
[TBL] [Abstract][Full Text] [Related]
19. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
Kader HA; Wenner WJ; Telega GW; Maller ES; Baldassano RN
J Clin Gastroenterol; 2000 Jun; 30(4):409-13. PubMed ID: 10875470
[TBL] [Abstract][Full Text] [Related]
20. Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance.
Park MS; Kim DH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Dis Sci; 2015 Jan; 60(1):195-204. PubMed ID: 25239495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
